Skip to main content
Premium Trial:

Request an Annual Quote

Battle? Won. War? Still Being Fought

Myriad Genetics won a significant victory last month when an appeals court upheld the company's gene patents. But now, The New York Times' Andrew Pollack says, the real battle starts for Myriad. Some experts say the company's test for the BRCA1 and BRCA2 mutations is "technologically outmoded, incomplete and too costly," Pollack reports. The University of Washington's Mary-Claire King, who led the team that discovered the BRCA mutations, tells Pollack that "science has moved beyond what these folks do," and that patients and their doctors need the most up-to-date information to make treatment decisions. Newer DNA sequencing techniques are faster and cheaper than the technology Myriad uses, and soon, Pollack adds, it may be cheaper to sequence an entire genome than to use Myriad's test. For its part, Myriad says it is prepared for the challenge. The company's major patents begin to expire in 2014, though Myriad says its patent protection should last until about 2018, and the company's executives say that will give them time to adapt to new technologies and diversify beyond the BRCA test.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.